813 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
AMGN Amgen Inc. $200.81 $129.98B N/A
Article Searches
Merck's Heart Failure Candidate Meets Goal in Phase III Study http://www.zacks.com/stock/news/627569/mercks-heart-failure-candidate-meets-goal-in-phase-iii-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-627569 Nov 19, 2019 - Merck (MRK) and German partner Bayer's vericiguat reduces the risk of heart failure hospitalization or cardiovascular death in patients with worsening chronic heart failure.
Top Stock Reports for Facebook, Bank of America & Home Depot http://www.zacks.com/research-daily/631034/top-stock-reports-for-facebook-bank-of-america-home-depot?cid=CS-ZC-FT-research_daily-631034 Nov 21, 2019 - Top Stock Reports for Facebook, Bank of America & Home Depot
Novartis (NVS) to Acquire The Medicines Company for $9.7B http://www.zacks.com/stock/news/636880/novartis-nvs-to-acquire-the-medicines-company-for-%2497b?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-636880 Nov 25, 2019 - Novartis (NVS) set to acquire The Medicines Company and add a promising candidate to its cardiovascular pipeline.
Merck's Keytruda Gets Nod in China for Difficult Lung Cancer http://www.zacks.com/stock/news/643382/mercks-keytruda-gets-nod-in-china-for-difficult-lung-cancer?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-643382 Nov 27, 2019 - Merck (MRK) receives the third approval of Keytruda for first-line non-small cell lung cancer patient population in China.
Biogen Up on New Data on Alzheimer's Candidate Aducanumab http://www.zacks.com/stock/news/657638/biogen-up-on-new-data-on-alzheimers-candidate-aducanumab?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-657638 Dec 06, 2019 - Biogen (BIIB) divulges new positive data on Alzheimer's candidate, aducanumab at CTAD. Stock rises.
Biotech ETFs Hit New Highs on Deal Activities http://www.zacks.com/stock/news/663878/biotech-etfs-hit-new-highs-on-deal-activities?cid=CS-ZC-FT-etf_news_and_commentary-663878 Dec 10, 2019 - Following the new deals in the healthcare space, a few biotech ETFs hit new highs.
Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar http://www.zacks.com/stock/news/665488/biotech-stock-roundup-ash-data-in-focus-amgen-gets-fda-nod-to-remicade-biosimilar?cid=CS-ZC-FT-analyst_blog|stock_roundup-665488 Dec 11, 2019 - The biotech sector witnesses pipeline updates from the annual ASH meet.
AbbVie's JAK Inhibitor Rinvoq Receives Approval for RA in EU http://www.zacks.com/stock/news/678331/abbvies-jak-inhibitor-rinvoq-receives-approval-for-ra-in-eu?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-678331 Dec 19, 2019 - AbbVie's (ABBV) oral JAK inhibitor, upadacitinib, receives approval in Europe for treating rheumatoid arthritis under the trade name of Rinvoq.
Merck's Keytruda Misses One of Two Goals in Lung Cancer Study http://www.zacks.com/stock/news/706462/mercks-keytruda-misses-one-of-two-goals-in-lung-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-706462 Jan 07, 2020 - Merck's (MRK) phase III first-line SCLC study fails to meet one of the two primary endpoints. It signs an oncology collaboration with Taiho Pharmaceutical and Astex Pharmaceuticals.
Know These 3 Facts to Avoid Paying Half Your Retirement Income to the IRS - January 13, 2020 http://www.zacks.com/stock/news/715571/know-these-3-facts-to-avoid-paying-half-your-retirement-income-to-the-irs-january-13-2020?cid=CS-ZC-FT-retirement_ideas|required_minimum_distribution-715571 Jan 13, 2020 - Like many investors, you're likely aiming to build a comfortable nest egg to ensure a comfortable retirement. Make sure you know all about what financial planners dub the accumulation and distribution phases of retirement planning.

Pages: 1...7576777879808182

<<<Page 80>